PL2328931T3 - Wybiórcze przeciwciała anty-hepcydyna-25 i ich zastosowania - Google Patents

Wybiórcze przeciwciała anty-hepcydyna-25 i ich zastosowania

Info

Publication number: PL2328931T3
Authority: PL; Poland
Prior art keywords: hepcidin; selective antibodies; antibodies; selective
Prior art date: 2008-08-06

Application number

PL09790908T

Other languages

English (en)

Inventor

Donmienne Doen Mun Leung

Peng Luan

Ying Tang

Derrick Ryan Witcher

Pia Pauliina Yachi

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-08-06

Filing date

2009-07-29

Publication date

2014-01-31

2009-07-29 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2014-01-31 Publication of PL2328931T3 publication Critical patent/PL2328931T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Analytical Chemistry (AREA)
Pathology (AREA)
Genetics & Genomics (AREA)
General Physics & Mathematics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

PL09790908T 2008-08-06 2009-07-29 Wybiórcze przeciwciała anty-hepcydyna-25 i ich zastosowania PL2328931T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US8655708P	2008-08-06	2008-08-06
PCT/US2009/052044 WO2010017070A1 (en)	2008-08-06	2009-07-29	Anti-hepcidin-25 selective antibodies and uses thereof
EP09790908.9A EP2328931B1 (en)	2008-08-06	2009-07-29	Anti-hepcidin-25 selective antibodies and uses thereof

Publications (1)

Publication Number	Publication Date
PL2328931T3 true PL2328931T3 (pl)	2014-01-31

Family

ID=41165490

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL09790908T PL2328931T3 (pl)	2008-08-06	2009-07-29	Wybiórcze przeciwciała anty-hepcydyna-25 i ich zastosowania

Country Status (20)

Country	Link
US (1)	US8609817B2 (pl)
EP (1)	EP2328931B1 (pl)
JP (1)	JP5730200B2 (pl)
KR (1)	KR101462307B1 (pl)
CN (1)	CN102112489B (pl)
AU (1)	AU2009279865B2 (pl)
BR (1)	BRPI0916624A2 (pl)
CA (1)	CA2733497C (pl)
DK (1)	DK2328931T3 (pl)
EA (1)	EA201170312A1 (pl)
ES (1)	ES2432018T3 (pl)
HK (1)	HK1156326A1 (pl)
IL (1)	IL210643A (pl)
MX (1)	MX2011001363A (pl)
NZ (1)	NZ590863A (pl)
PL (1)	PL2328931T3 (pl)
PT (1)	PT2328931E (pl)
UA (1)	UA103032C2 (pl)
WO (1)	WO2010017070A1 (pl)
ZA (1)	ZA201100261B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4571620B2 (ja) *	2003-04-01	2010-10-27	インセルム（アンスティチュ・ナショナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル）	肝炎ｃウイルスｅ１ｅ２複合体に対する抗体、ｈｃｖ粒子の組成物及び医薬組成物
TWI409276B (zh) *	2007-11-02	2013-09-21	Lilly Co Eli	抗－海帕西啶（ｈｅｐｃｉｄｉｎ）抗體及其用途
CA2808392C (en)	2010-08-16	2020-03-10	Pieris Ag	Binding proteins for hepcidin
AU2012350654C1 (en)	2011-12-12	2018-05-10	Pieris Ag	Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
US10316103B1 (en)	2012-03-30	2019-06-11	Biocare Medical, Llc	Systems and methods for anti-Uroplakin III antibodies
US20140120560A1 (en) *	2012-10-26	2014-05-01	Claresa Levetan	Generation of new pancreatic beta cells
US10429390B2 (en)	2012-12-18	2019-10-01	Biocare Medical, Llc	Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
US9657098B2 (en) *	2013-03-15	2017-05-23	Intrinsic Lifesciences, Llc	Anti-hepcidin antibodies and uses thereof
JP6506267B2 (ja) *	2013-10-03	2019-04-24	バイオケアメディカル，エルエルシー	抗ｓｏｘ１０抗体のシステムおよび方法
JPWO2016027469A1 (ja) *	2014-08-21	2017-06-01	国立大学法人旭川医科大学	ヘプシジンのスプライシングバリアント並びに該バリアントを指標とした癌の診断方法
CA2961917A1 (en)	2014-09-22	2016-03-31	Intrinsic Lifesciences Llc	Humanized anti-hepcidin antibodies and uses thereof
EP3268027B1 (en)	2015-03-13	2022-11-02	Institut National de la Santé et de la Recherche Médicale (INSERM)	Hepcidin antagonists for use in the treatment of inflammation
WO2018063963A1 (en) *	2016-09-28	2018-04-05	Board Of Regents, The University Of Texas System	Antibody and protein therapeutic formulations and uses thereof
BR112019013107A2 (pt)	2016-12-22	2019-12-17	Univ Degli Studi Magna Graecia Catanzaro	anticorpos, molécula de ligação, receptor de antígeno quimérico, vetor de expressão, composição farmacêutica, linfócito, ácido nucleico, célula de hibridoma, método para a produção do anticorpo monoclonal e usos
WO2018234538A1 (en)	2017-06-23	2018-12-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	ANTAGONIST OR AGONIST OF HEPCIDINE FOR USE IN THE TREATMENT OF DYSREGULATION OF MO AND / OR MN METABOLISM
CN109948371B (zh) *	2019-03-07	2021-06-25	深圳市智税链科技有限公司	为区块链节点发放身份证书的方法及相关装置
JPWO2022154121A1 (pl) *	2021-01-18	2022-07-21

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU3774300A (en)	1999-06-02	2000-12-18	Genentech Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6262247B1 (en)	1999-08-30	2001-07-17	Incyte Genomics, Inc.	Polycyclic aromatic hydrocarbon induced molecules
CN1612746B (zh)	2001-05-25	2010-09-22	国家健康与医学研究院	Hepcidin作为制备铁稳态调节剂的用途
CN1173737C (zh)	2002-10-21	2004-11-03	钱忠明	Hepcidin(海魄喜定)在制药中的应用
JP4638350B2 (ja)	2002-11-19	2011-02-23	ディーアールジー・インターナショナル，インコーポレイテッド	ヒトまたは動物の組織、血液もしくは体液中のヘプシジンの存在または量を検出する方法
US8017737B2 (en)	2002-11-19	2011-09-13	Hasan Kulaksiz	Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
US7411048B2 (en)	2002-11-19	2008-08-12	Drg International, Inc.	Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
WO2005005604A2 (en)	2003-06-30	2005-01-20	Centocor, Inc.	Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
WO2005033327A2 (en)	2003-09-29	2005-04-14	Biosite Incorporated	Methods and compositions for the diagnosis of sepsis
AU2003271174A1 (en) *	2003-10-10	2005-04-27	Chugai Seiyaku Kabushiki Kaisha	Double specific antibodies substituting for functional protein
US7723063B2 (en) *	2004-04-28	2010-05-25	Intrinsic Lifesciences	Methods for measuring levels of bioactive human hepcidin
CA2602088C (en)	2005-03-11	2021-07-27	Ciphergen Biosystems, Inc.	Biomarkers for ovarian cancer and endometrial cancer
TW201307390A (zh)	2007-02-02	2013-02-16	Amgen Inc	海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法
GR1006896B (el)	2007-08-24	2010-07-20	Ελληνικο Ινστιτουτο Παστερ,	Μεθοδος παραγωγης μιας πεπτιδικης ορμονης
ATE553778T1 (de) *	2007-10-02	2012-05-15	Inst Nat Sante Rech Med	Für humanes hepcidin spezifische antikörper
TWI409276B (zh) *	2007-11-02	2013-09-21	Lilly Co Eli	抗－海帕西啶（ｈｅｐｃｉｄｉｎ）抗體及其用途
EP2294087B1 (en)	2008-05-01	2014-05-14	Amgen, Inc.	Anti-hepcidin antibodies and methods of use

2009
- 2009-07-29 EP EP09790908.9A patent/EP2328931B1/en active Active
- 2009-07-29 PL PL09790908T patent/PL2328931T3/pl unknown
- 2009-07-29 BR BRPI0916624A patent/BRPI0916624A2/pt not_active IP Right Cessation
- 2009-07-29 CA CA2733497A patent/CA2733497C/en active Active
- 2009-07-29 EA EA201170312A patent/EA201170312A1/ru unknown
- 2009-07-29 NZ NZ590863A patent/NZ590863A/xx not_active IP Right Cessation
- 2009-07-29 AU AU2009279865A patent/AU2009279865B2/en not_active Ceased
- 2009-07-29 WO PCT/US2009/052044 patent/WO2010017070A1/en active Application Filing
- 2009-07-29 MX MX2011001363A patent/MX2011001363A/es active IP Right Grant
- 2009-07-29 DK DK09790908.9T patent/DK2328931T3/da active
- 2009-07-29 PT PT97909089T patent/PT2328931E/pt unknown
- 2009-07-29 UA UAA201101111A patent/UA103032C2/uk unknown
- 2009-07-29 ES ES09790908T patent/ES2432018T3/es active Active
- 2009-07-29 JP JP2011522119A patent/JP5730200B2/ja not_active Expired - Fee Related
- 2009-07-29 US US13/055,201 patent/US8609817B2/en not_active Expired - Fee Related
- 2009-07-29 KR KR1020117002748A patent/KR101462307B1/ko not_active Expired - Fee Related
- 2009-07-29 CN CN200980129864.0A patent/CN102112489B/zh not_active Expired - Fee Related
2011
- 2011-01-10 ZA ZA2011/00261A patent/ZA201100261B/en unknown
- 2011-01-13 IL IL210643A patent/IL210643A/en not_active IP Right Cessation
- 2011-10-04 HK HK11110483.0A patent/HK1156326A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
JP2011530514A (ja)	2011-12-22
CA2733497A1 (en)	2010-02-11
CN102112489A (zh)	2011-06-29
UA103032C2 (uk)	2013-09-10
IL210643A0 (en)	2011-03-31
ZA201100261B (en)	2012-06-27
HK1156326A1 (en)	2012-06-08
DK2328931T3 (da)	2013-09-30
BRPI0916624A2 (pt)	2015-12-01
EP2328931B1 (en)	2013-08-14
IL210643A (en)	2015-09-24
WO2010017070A1 (en)	2010-02-11
EA201170312A1 (ru)	2012-03-30
CA2733497C (en)	2015-06-02
PT2328931E (pt)	2013-11-07
US8609817B2 (en)	2013-12-17
NZ590863A (en)	2012-10-26
MX2011001363A (es)	2011-04-26
AU2009279865A1 (en)	2010-02-11
US20110189190A1 (en)	2011-08-04
CN102112489B (zh)	2014-05-14
AU2009279865B2 (en)	2013-10-10
KR101462307B1 (ko)	2014-11-17
KR20110031963A (ko)	2011-03-29
EP2328931A1 (en)	2011-06-08
JP5730200B2 (ja)	2015-06-03
ES2432018T3 (es)	2013-11-29

Publication	Publication Date	Title
IL209309A0 (en)	2011-01-31	Anti-fn14 antibodies and uses thereof
IL250624B (en)	2018-02-28	Anti-fgfr3 antibodies and methods of using them
HK1156326A1 (en)	2012-06-08	Anti-hepcidin-25 selective antibodies and uses thereof
IL216731A (en)	2015-04-30	And antibodies against p95 – her2 and their uses
IL200012A0 (en)	2010-04-15	Anti-robo4 antibodies and uses therefor
IL205355A0 (en)	2010-12-30	Anti- hepcidin antibodies and uses thereof
PL2099826T3 (pl)	2014-04-30	Przeciwciało przeciwko beta-amyloidowi i jego zastosowania
EP2494062A4 (en)	2013-05-29	ANTI-GLP-1R ANTIBODIES AND THEIR USES
ZA201107486B (en)	2012-06-27	Anti-tnf-x antibodies and their uses
PL2354161T3 (pl)	2016-01-29	Przeciwciało anty -NR10 i jego zastosowanie
EP2334330A4 (en)	2013-05-15	ANTI-CD147 ANTIBODIES, METHODS, AND USES
HK1195776A1 (zh)	2014-11-21	-α 抗-α 抗體及其應用
IL207129A0 (en)	2010-12-30	Ron antibodies and uses thereof
IL220536A0 (en)	2012-08-30	Anti - bv8 antibodies and uses thereof
HK1210026A1 (en)	2016-04-15	Thiol-functionalising reagents and their uses
SI2354161T1 (sl)	2015-12-31	Anti-NR10 protitelo in njegova uporaba
IL219136A0 (en)	2012-06-28	Anti-hepsin antibodies and methods using same
GB0903151D0 (en)	2009-04-08	Antibody uses and methods
IL214527A0 (en)	2011-09-27	Anti-mst1r antibodies and uses thereof
HK1158977A1 (zh)	2012-07-27	抗膜鐵轉運蛋白單克隆抗體及其用途
GB0812277D0 (en)	2008-08-13	Antibody and uses thereof
ZA200905136B (en)	2010-09-29	Anti-robo4 antibodies and uses therefor